Released: Last reviewed:
FDA, CMS and pricing developments, newest first, each with its primary source and what it means if you pay cash.
Lilly said it will report third-quarter 2026 results on October 29. Medicare open enrollment runs October 15 to December 7, with changes effective January 1.
What it means for cash-pay patients: Watch the Lilly call for Zepbound and Foundayo self-pay trends and any 2027 LillyDirect pricing.
Source: investingnews.com · confirmed
CNN reported clinicians seeing more patients with anorexia using GLP-1s, some obtained online after little screening. One patient said he misstated his weight to a telehealth company; Hims & Hers told CNN eating-disorder screening is mandatory in its process.
What it means for cash-pay patients: Expect closer scrutiny of questionnaire-only intake. A careful program asks about eating-disorder history and checks weight and BMI.
Source: edition.cnn.com · confirmed (press report)
CNBC reported that Walmart will cover more than 250 prescriptions at no cost to employees in 2027, including Ozempic and Mounjaro for type 2 diabetes after prior authorization. GLP-1s for weight loss remain excluded.
What it means for cash-pay patients: Employees who want a GLP-1 for weight loss stay on cash pay.
Source: www.cnbc.com · confirmed (press report)
Mochi’s own blog post, first published in August and updated September 18, lists compounded semaglutide at $60–$99 a month and tirzepatide at $90–$199 by dose, with membership billed separately. A press article on October 13 covered it alongside a new lab-testing service.
What it means for cash-pay patients: Entry doses got cheaper at Mochi; higher doses cost what they did before, plus membership.
Source: joinmochi.com · confirmed
A paid press release described Ozari One (semaglutide $86 and tirzepatide $125 a month, billed quarterly, not in California) and Ozari Select (choice of additive, $99–$235 by billing term), both at the same price for every dose and filled by five named 503A pharmacies.
What it means for cash-pay patients: Not yet in our index: we have not read Ozari’s own pricing pages.
Source: finance.yahoo.com · reported (company release)
FDA posted letters 737806 (onlinegenericmedicine.com, “Semanat”) and 737810 (cheapmedicineshop.com, “Semanext”), dated September 23 and 24, saying the injectable semaglutide they sold is unapproved and misbranded.
What it means for cash-pay patients: Online “generic semaglutide” is not an FDA-approved product. Our full report.
Source: www.fda.gov · confirmed
FDA’s consumer page, current as of October 1, lists telehealth red flags, says compounded multi-dose vials should be discarded 28 days after first use, warns against salt forms and states that retatrutide and cagrilintide cannot be used in compounding under federal law.
What it means for cash-pay patients: Use it as a checklist when a price looks too good to be true.
Source: www.fda.gov · confirmed
Under the state’s FY2027 budget, Rhode Island Medicaid ended coverage of Foundayo, Saxenda, Wegovy and Zepbound when prescribed solely for weight loss, effective October 1. Coverage continues for diabetes and other approved uses.
What it means for cash-pay patients: Affected members must self-pay or stop treatment.
Source: www.point32health.org · confirmed
CMS pages say the $50-copay Medicare GLP-1 Bridge runs from July 1, 2026 to December 31, 2027, outside the Part D benefit, and that the BALANCE model will not launch in Medicare in 2027.
What it means for cash-pay patients: Eligible Medicare patients have a low-cost brand option through 2027.
Source: www.cms.gov · confirmed
FDA announced charges in the Middle District of Florida against two Indian nationals accused of distributing counterfeit Ozempic between 2023 and 2024. An indictment is an allegation, not a conviction.
What it means for cash-pay patients: Buy brand GLP-1s only through licensed pharmacies or the manufacturers’ programs.
Source: www.fda.gov · confirmed
At its Capital Markets Day, Novo said the Wegovy pill had passed 7 million prescriptions in 2026, with about 90% self-pay, and described partnerships with nine or more telehealth companies.
What it means for cash-pay patients: Cash pay is now the main route to the Wegovy pill.
Source: www.novonordisk.com · confirmed
Letter 738238, posted September 22, says Empower’s compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin “appear to be essentially copies” of approved drugs and cites insanitary conditions.
What it means for cash-pay patients: Ask any program which pharmacy fills your prescription. Empower profile.
Source: www.fda.gov · confirmed
FDA removed semaglutide injection from its drug shortage list, which ended the shortage-based basis for widespread compounding of copies.
Source: U.S. FDA (fda.gov) · confirmed
FDA confirmed the tirzepatide shortage was resolved after reviewing Lilly’s supply data.
Source: U.S. FDA (fda.gov) · confirmed
FDA approved Wegovy to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight, based on the SELECT trial.
Source: U.S. FDA (fda.gov) · confirmed
FDA approved semaglutide 2.4 mg (Wegovy) for chronic weight management in adults with obesity or overweight with a weight-related condition.
Source: U.S. FDA (fda.gov) · confirmed
Items marked “press report” or “company release” are not primary sources. Corrections: americantelehealthreview@gmail.com.